Designer T-cells and T-cell receptors for customised cancer immunotherapies

Sewell, Andrew K. ORCID: https://orcid.org/0000-0003-3194-3135 and Legut, Mateusz 2018. Designer T-cells and T-cell receptors for customised cancer immunotherapies. Current Opinion in Pharmacology 41 , pp. 96-103. 10.1016/j.coph.2018.05.005

Preview

PDF - Accepted Post-Print Version Download (2MB) | Preview

Abstract

Cancer immunotherapy, focused on harnessing and empowering the immune system against tumours, has transformed modern oncology. One of the most promising avenues in development involves using genetically engineered T-cells to target cancer antigens via specific T-cell receptors (TCRs). TCRs have a naturally low affinity towards cancer-associated antigens, and therefore show scope for improvement. Here we describe approaches to procure TCRs with enhanced affinity and specificity towards cancer, using protein engineering or selection of natural TCRs from unadulterated repertoires. In particular, we discuss novel methods facilitating the targeting of tumour-specific mutations. Finally, we provide a prospective outlook on the potential development of novel, off-the-shelf immunotherapies by leveraging recent advances in genome editing.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	1471-4892
Funders:	Thomson Marconi Sonar, Wellcome Trust
Date of First Compliant Deposit:	29 May 2018
Date of Acceptance:	15 May 2018
Last Modified:	20 Nov 2024 02:30
URI:	https://orca.cardiff.ac.uk/id/eprint/111828

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item